The Grünenthal Group is an entrepreneurial, science-based pharmaceutical company specialized in pain, gout and inflammation. We are a fully integrated research & development company with a long track record of bringing innovative pain treatments and state-of-the-art technologies to patients.
We are an independent, family-owned company with headquarters in Aachen, Germany. We are present in 32 countries with affiliates in Europe, Latin America and the USA. Our products are sold in more than 155 countries and we employ around 5,200 employees worldwide.
For us, innovation goes beyond drug development. Our innovation is built on expert knowledge of disease-pathophysiology’s, understanding of the patient, the use of big data and state-of-the-art technologies such as devices that result in innovative solutions for the patients need.
Ambition is welcome at Grünenthal. Whether you’re a world-class scientist or a talented graduate, together we drive cutting-edge research projects and develop products of the future. Grünenthal offers a culture of opportunity. Join us!
The role of the placebo effect has become a focus in pain research due to its potential to reduce separation between the drug and control arms, and so influence the outcome in randomised controlled trials (RCTs).